{
    "clinical_study": {
        "@rank": "4944", 
        "arm_group": [
            {
                "arm_group_label": "Vitamin D2 Treatment", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "1,25(OH)2 Vitamin D3", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "low protein diet", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "normal protein diet", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Multi-center, prospective, randomized, controlled study to verify the clinical effectiveness\n      of K / DOQI guidelines. The efficiency and safety of Vitamin D2 and low protein diet\n      treatment for prevention and treatment of CKD-MBD and malnutrition in CKD3-5 (ND) patients."
        }, 
        "brief_title": "Optimizing Treatment Programs for Chronic Kidney Disease-mineral and Bone Disorder and Malnutrition", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Vitamin D Deficiency", 
            "Malnutrition"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Vitamin D Deficiency", 
                "Malnutrition", 
                "Renal Insufficiency, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will enroll chronic kidney disease patients, stage 3 to 5ND, who have chronic\n      kidney disease mineral and bone disease (CKD-MBD) and malnutrition as defined by Kidney\n      Disease Improvement Global Outcome (KDIGO) Guidelines. Patients in five centers will be\n      randomized. A total of 600 patients will be enrolled, 150 patients receiving Vitamin D2\n      treatment virus 150 patients receiving calcitriol treatment, and another 150 patients\n      receiving low protein diet virus 150 patients receiving normal protein diet. Outcomes will\n      be assessed as proportion of patients achieving target blood levels on calcium, phosphorus,\n      parathyroid hormone, 25 hydroxyvitamin D, albumin and hemoglobin. Other outcomes will also\n      be assessed, which include secondary hyperparathyroidism (sHPT), vascular calcification,\n      cardiovascular diseases, nutritional status and quality of life."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with age between 18-80 years.\n\n          -  Patients with chronic kidney disease stage 3 to 5, and concurrent chronic kidney\n             disease mineral and bone disorder and malnutrition\n\n        Exclusion Criteria:\n\n          -  Renal artery stenosis, inherent renal malformation, solitary kidney, or malignancy in\n             urinary system.\n\n          -  Active system immunity diseases.\n\n          -  History of liver failure\n\n          -  History of intestinal malabsorption or chronic diarrhea\n\n          -  Treatment with phenobarbital, phenytoin, rifampicin, sucralfate, steroids, digoxin,\n             or other medications that could affect vitamin D metabolism\n\n          -  Primary hyperparathyroidism\n\n          -  Treatment with cinacalcet or other calcimimetic within the past 6 months\n\n          -  Anticipated dialysis within 6 months after randomization\n\n          -  Have an unstable medical condition, defined as having been hospitalized within 30\n             days before screening, the expectation of recurrent hospital admissions or life\n             expectancy of less than 6 months in the judgment of the investigator\n\n          -  Subject is currently enrolled in, or fewer than 30 days have passed since subject has\n             completed another investigational device or drug study(s); or subject is receiving\n             another investigational agent(s).\n\n          -  Current treatment with vitamin D 50,000 IU\n\n          -  Using glucocorticoid or immunosuppressive agents.\n\n          -  Acute renal dysfunction.\n\n          -  The expected live time is less than 2 years.\n\n          -  Pregnant or lactating woman.\n\n          -  Suffered from acute myocardial infraction, acute congestive heart failure, or stroke\n             in last 6 months.\n\n          -  Patients whose concurrent illnesses, disability, or geographical residence would\n             hamper attendance at required study visit."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02005302", 
            "org_study_id": "BJFH-EC/2013-076", 
            "secondary_id": "D131100004713001"
        }, 
        "intervention": [
            {
                "arm_group_label": "1,25(OH)2 Vitamin D3", 
                "description": "Oral 1,25(OH)2 Vitamin D3 by 0.25 microgram once daily at start and regulate the dose according to the changes of blood levels of 25(OH)Vit D, calcium, phosphorus, and intact parathyroid hormone.", 
                "intervention_name": "1,25(OH)2 Vitamin D3", 
                "intervention_type": "Drug", 
                "other_name": "Active Vit D3"
            }, 
            {
                "arm_group_label": "Vitamin D2 Treatment", 
                "description": "Oral Vit D2 1.25mg(50,000 unit) once weekly as a start and maintain 1.25mg(50,000 unit) once monthly according to the blood 25(OH)vitamin D level.", 
                "intervention_name": "Vitamin D2", 
                "intervention_type": "Drug", 
                "other_name": "Vit D2"
            }, 
            {
                "arm_group_label": "low protein diet", 
                "description": "Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of 0.6g-0.8g/kg/d.", 
                "intervention_name": "low protein diet", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "normal protein diet", 
                "description": "Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of more than 0.8g/kg/d.", 
                "intervention_name": "normal protein diet", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cholecalciferol", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "chronic kidney disease", 
            "mineral and bone disease", 
            "Malnutrition", 
            "Vitamin D", 
            "low protein diet"
        ], 
        "lastchanged_date": "December 4, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100050"
                    }, 
                    "name": "Beijing Friedship Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100000"
                    }, 
                    "name": "Sino-Japanese Friendship Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100000"
                    }, 
                    "name": "Beijing XuanWu Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100000"
                    }, 
                    "name": "People's Liberation Army Air Force General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100000"
                    }, 
                    "name": "People's Liberation Army General Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "4", 
        "official_title": "Study of Vitamin D2 Virus 1,25(OH)2-Vitamin D3 and Normal Protein Diet Virus Low Protein Diet in the Treatment of CKD-MBD and Malnutrition for Progressive CKD Patients", 
        "overall_official": {
            "affiliation": "Nephrology Department of Beijing Friendship Hospita", 
            "last_name": "Wenhu Liu, Doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "China: Beijing Municipal Science and Technology Commission", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The blood levels of calcium, phosphorus,and intact parathyroid (iPTH) will be detected every three months. The values during follow-up will be compared to the baseline.", 
                "measure": "The changes on the blood levels of calcium, phosphorus, and intact parathyroid (iPTH) hormone during 36 months", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "The blood levels of albumin, prealbumin, transferrin and hemoglobin will be detected every three months. The values during follow-up will be compared to the baseline.", 
                "measure": "The changes on the clinical indicators of nutritional status", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02005302"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Beijing Friendship Hospital", 
            "investigator_full_name": "Wenhu Liu", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "The changes of the blood 25(OH)Vitamin D level", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "Assess the quality of life for patients in accordance with KDQOL-SF scale every 6 month. The values during follow-up will be compared to the baseline.", 
                "measure": "The changes of the quality of life", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }
        ], 
        "source": "Beijing Friendship Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Beijing Municipal Science & Technology Commission", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Wenhu Liu", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}